Your browser doesn't support javascript.
loading
In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model.
Fennell, D A; Corbo, M V; Dean, N M; Monia, B P; Cotter, F E.
Afiliación
  • Fennell DA; Department of Experimental Haematology, St Bartholomew's and The Royal London School of Medicine & Dentistry, Turner Street, London E1 2AD, UK.
Br J Haematol ; 112(3): 706-13, 2001 Mar.
Article en En | MEDLINE | ID: mdl-11260076
Bcl-XL, a member of the Bcl-2-related anti-apoptosis protein family, antagonizes a diverse range of apoptosis-inducing stimuli by preventing mitochondrial permeability transition, release of apoptogenic factors including cytochrome C, and caspase activation. We have tested the hypothesis that the susceptibility of Bcl-XL-expressing leukaemic cells to apoptosis induced by VP16 (etoposide) can be enhanced by pharmacological downregulation of Bcl-XL in vivo. Two subcutaneous xenograft models of B-cell leukaemia-employing SEMK-2 and BV173 cell lines were established in severe combined immunodeficient/non-obese diabetic mice followed by 14 d of continuous subcutaneous administration of Bcl-XL-specific second generation oligonucleotides ISIS 16009 or ISIS 15999. Tumours were disaggregated, enabling investigation of Bcl-XL expression and apoptosis susceptibility at single-cell resolution using cytofluorimetry. Marked sequence-specific reduction of Bcl-XL was associated with sequence-specific enhancement of VP16-induced mitochondrial permeability transition, caspase-3 activation and loss of membrane asymmetry. A negative correlation between Bcl-XL expression and apoptosis susceptibility was observed, together with a positive correlation with respect to a reduced redox state. Bcl-XL downregulation reduces the threshold for VP16-induced apoptosis by potentiating mitochondrial dysfunction and its sequelae, and therefore presents a novel therapeutic strategy for reversing chemoresistance.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Oligonucleótidos Antisentido / Inmunodeficiencia Combinada Grave / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-bcl-2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Br J Haematol Año: 2001 Tipo del documento: Article Pais de publicación: Reino Unido
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Terapia Genética / Oligonucleótidos Antisentido / Inmunodeficiencia Combinada Grave / Resistencia a Antineoplásicos / Proteínas Proto-Oncogénicas c-bcl-2 Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Br J Haematol Año: 2001 Tipo del documento: Article Pais de publicación: Reino Unido